Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | Neutral | Guggenheim | |
| 2/6/2025 | Buy → Neutral | BTIG Research | |
| 10/24/2024 | $27.00 | Buy | UBS |
| 10/14/2024 | $26.00 → $19.00 | Buy → Hold | Stifel |
| 12/22/2023 | $26.00 | Buy | Mizuho |
| 8/11/2023 | $31.00 | Buy | BofA Securities |
| 7/27/2023 | $10.50 | Sector Perform | Scotiabank |
| 5/17/2023 | $31.00 | Buy | BTIG Research |
4 - Kura Oncology, Inc. (0001422143) (Issuer)
4 - Kura Oncology, Inc. (0001422143) (Issuer)
4 - Kura Oncology, Inc. (0001422143) (Issuer)
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially best-in-class safety profile, once-daily administration, and ease of co-administration with common supportive medications in adult patients with R/R NPM1-mutated AML – – KOMZIFTI approval granted with no Boxed Warning related to QTc prolongation or Torsades de Pointes – – Kura Oncology will host a
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference: Jefferies Global Healthcare ConferenceNovember 19, 20253:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT A live audio webcast will be available in the Investors section of Kura's website at https://kuraoncology.com/, with an archived replay available following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 21,750 shares of common stock to a new non-executive employee under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employee's employment in accordance with Nasda
Guggenheim initiated coverage of Kura Oncology with a rating of Neutral
BTIG Research downgraded Kura Oncology from Buy to Neutral
UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00
4 - Kura Oncology, Inc. (0001422143) (Issuer)
144 - Kura Oncology, Inc. (0001422143) (Subject)
144 - Kura Oncology, Inc. (0001422143) (Subject)
SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff
SC 13G - Kura Oncology, Inc. (0001422143) (Subject)
SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially best-in-class safety profile, once-daily administration, and ease of co-administration with common supportive medications in adult patients with R/R NPM1-mutated AML – – KOMZIFTI approval granted with no Boxed Warning related to QTc prolongation or Torsades de Pointes – – Kura Oncology will host a
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemotherapy in frontline and R/R NPM1-m AML – – Clinical data at ESMO 2025 Congress highlight promise of second strategic program – FTIs darlifarnib and tipifarnib show promising safety profile
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the investor relations section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a clin